These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 28762839)

  • 1. New treatment options for lower respiratory tract infections.
    Kocsis B; Szabo D
    Expert Opin Pharmacother; 2017 Sep; 18(13):1345-1355. PubMed ID: 28762839
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Zabofloxacin for chronic bronchitis.
    Kocsis B; Szabo D
    Drugs Today (Barc); 2016 Sep; 52(9):495-500. PubMed ID: 27883116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Solithromycin for the treatment of community-acquired bacterial pneumonia.
    Viasus D; Ramos O; Ramos L; Simonetti AF; Carratalà J
    Expert Rev Respir Med; 2017 Jan; 11(1):5-12. PubMed ID: 27753516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delafloxacin for the treatment of respiratory and skin infections.
    Bassetti M; Della Siega P; Pecori D; Scarparo C; Righi E
    Expert Opin Investig Drugs; 2015 Mar; 24(3):433-42. PubMed ID: 25604710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical management of respiratory tract infections in the community: experience with telithromycin.
    Quintiliani R
    Infection; 2001 Dec; 29 Suppl 2():16-22. PubMed ID: 11785852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-inflammatory effects of macrolides--an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions?
    Amsden GW
    J Antimicrob Chemother; 2005 Jan; 55(1):10-21. PubMed ID: 15590715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacotherapy for lower respiratory tract infections.
    Liapikou A; Torres A
    Expert Opin Pharmacother; 2014 Nov; 15(16):2307-18. PubMed ID: 25216725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renaissance of antibiotics against difficult infections: Focus on oritavancin and new ketolides and quinolones.
    Van Bambeke F
    Ann Med; 2014 Nov; 46(7):512-29. PubMed ID: 25058176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical efficacy of ketolides in the treatment of respiratory tract infections.
    Reinert RR
    J Antimicrob Chemother; 2004 Jun; 53(6):918-27. PubMed ID: 15117934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute lower respiratory infections: real-world evidence of antibiotic prescription pattern and costs from a large administrative Italian database.
    Calabria S; Dondi L; Ronconi G; Piccinni C; Pedrini A; Esposito I; Addesi A; Maggioni AP; Martini N
    Fam Pract; 2022 Jul; 39(4):669-677. PubMed ID: 35078213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. From macrolides to ketolides: What is available for the treatment of outpatient respiratory tract infections?
    Carter PL
    Postgrad Med; 2002 Sep; 112(3 Suppl):18-25. PubMed ID: 19667591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Telithromycin: the first ketolide antibacterial for the treatment of community-acquired respiratory tract infections.
    Lorenz J
    Int J Clin Pract; 2003; 57(6):519-29. PubMed ID: 12918892
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delafloxacin as a treatment option for community-acquired pneumonia infection.
    Nascimento-Carvalho CM
    Expert Opin Pharmacother; 2021 Oct; 22(15):1975-1982. PubMed ID: 34346823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Barriers to the effective management of respiratory tract infections in the community.
    Saginur R
    Infection; 2001 Dec; 29 Suppl 2():3-10. PubMed ID: 11785853
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The solithromycin journey-It is all in the chemistry.
    Fernandes P; Martens E; Bertrand D; Pereira D
    Bioorg Med Chem; 2016 Dec; 24(24):6420-6428. PubMed ID: 27595539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New therapeutic options for respiratory tract infections.
    Bassetti M; Righi E; Carnelutti A
    Curr Opin Infect Dis; 2016 Apr; 29(2):178-86. PubMed ID: 26871402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Solithromycin: A Novel Fluoroketolide for the Treatment of Community-Acquired Bacterial Pneumonia.
    Zhanel GG; Hartel E; Adam H; Zelenitsky S; Zhanel MA; Golden A; Schweizer F; Gorityala B; Lagacé-Wiens PR; Walkty AJ; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA
    Drugs; 2016 Dec; 76(18):1737-1757. PubMed ID: 27909995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SOLITAIRE-IV: A Randomized, Double-Blind, Multicenter Study Comparing the Efficacy and Safety of Intravenous-to-Oral Solithromycin to Intravenous-to-Oral Moxifloxacin for Treatment of Community-Acquired Bacterial Pneumonia.
    File TM; Rewerska B; Vucinic-Mihailovic V; Gonong JRV; Das AF; Keedy K; Taylor D; Sheets A; Fernandes P; Oldach D; Jamieson BD
    Clin Infect Dis; 2016 Oct; 63(8):1007-1016. PubMed ID: 27448679
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Acute respiratory tract infection in chronically ill patients. germ spectrum different than in healthy persons].
    MMW Fortschr Med; 2003 Dec; 145(49):61. PubMed ID: 14964003
    [No Abstract]   [Full Text] [Related]  

  • 20. Intracellular concentrations of antibacterial agents and related clinical implications.
    Butts JD
    Clin Pharmacokinet; 1994 Jul; 27(1):63-84. PubMed ID: 7955773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.